Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ 6.04MDepreciation, Amortization & Accretion
VS
Market
Sector
Industry
History
$ 1.65Close
$ 0.67 - $ 1.82 52-Week Range
Ticker Information
Ticker
CHRSCompany Name
COHERUS ONCOLOGY INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQCOHERUS ONCOLOGY INC - Depreciation, Amortization & Accretion Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
CHRS - DepAmor Historical data
| Date | Depreciation, Amortization & Accretion |
|---|---|
| 6/30/2025 | $ 6.04M |
| 3/31/2025 | $ 6.21M |
| 12/31/2024 | $ 6.67M |
| 9/30/2024 | $ 5.77M |
| 6/30/2024 | $ 5.85M |
| 3/31/2024 | $ 6.83M |
| 12/31/2023 | $ 6.27M |
| 9/30/2023 | $ 5.79M |
| 6/30/2023 | $ 5.15M |
| 3/31/2023 | $ 3.88M |
Key Performance Insights, Last 5 Years
- COHERUS ONCOLOGY INC's latest trailing twelve months (TTM) DepAmor stands at $ 5.15M.
- Over the past 5 years, COHERUS ONCOLOGY INC's average DepAmor has been $ 5.39M.
- The median DepAmor for COHERUS ONCOLOGY INC during this period was $ 5.48M
- COHERUS ONCOLOGY INC reached its highest DepAmor over the past 5 years at $ 6.83M.
- The lowest DepAmor recorded by COHERUS ONCOLOGY INC in the same timeframe $ 3.7M
COHERUS ONCOLOGY INC's DepAmor vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
DepAmor Benchmarks
Similar metrics to DepAmor:
- Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) - [Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
- Depreciation and Amortization Margin - [Calculation] The company’s deprecation and amortization [DepAmor] expressed as a percentage of [Revenue].
- Net Cash Flow - Operations - [Cash Flow Statement] Cash flow from operations represents the amount of cash inflow (outflow) that a company generates (consumes) from operating activities. Similar to Net Income [NetIncCmn] but harder to manipulate and ignoring effects of non-cash charges like depreciation.
- Stock Based Compensation - [Cash Flow Statement] Stock Based Compensation, also called Share Based Compensation or Equity Compensation, is a method of paying directors, executives and employees with equity in the business. As non-cash expense, this element is added back when calculating net cash generated by operating activities [NCFO].
- Earnings per Share - [Income Statement] Earnings per Share as calculated and reported by the company. Approximates to the amount of net income [NetIncCmn] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
Definition of Depreciation, Amortization & Accretion
[Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.CHRS - Depreciation, Amortization & Accretion, Last 5 years
$ 3.7M
Minimum
Dec 31, 2022
$ 6.83M
Maximum
Mar 31, 2024
$ 5.39M
Average
$ 5.48M
Median
DepAmor Benchmark AnalysisMarket
The chart above depicts the distribution of DepAmor for companies in the Total Stock Market. The average DepAmor of the companies is $ 24.06M with a standard deviation of $ 33.58M.
The following table provides additional summary stats:
DepAmor in the Market:
| filtered constituents | 3.16K |
|---|---|
| min | $ -81M |
| max | $ 135.97M |
| average | $ 24.06M |
| median | $ 6.83M |
| std | $ 33.58M |